Qure.ai Partners with xWave Technologies to Enhance Radiology Diagnostic Precision

Mumbai headquartered Qure.ai, a medical artificial intelligence (AI) solution provider, has joined forces with xWave Technologies, a cloud-based Clinical Decision Support (CDS) system catering to radiology referrals. The companies have joined hands to strengthen market access, co-develop products, and integrate efforts to offer advanced global healthcare solutions that address critical healthcare challenges.

This synergy would lead to swifter patient outcomes and reduced unnecessary diagnostic appointments. The convergence of precise initial testing and AI-powered efficiency has the potential to aid hospitals in tactically managing projected healthcare demands in the upcoming winter period.

By amalgamating medical AI technology with clinical decision support systems, radiology units can streamline operations and enhance diagnostic precision. This inventive approach conserves time and resources while advancing patient results, directing overburdened radiology teams toward judicious selection and reporting pertinent diagnostic tests.

Highlighting the potential for collaboration, Darren Stephens, Qure.ai's senior vice-president & commercial head for the UK and Europe, underlined the intention to optimise the radiology pathway.

He explained that the integration of clinical decision support and AI in imaging would strengthen the assistance provided to clinicians.

The Clinical Decision Support (CDS) system by xWave has been developed in collaboration with the European Society of Radiology (iGuide) and the Royal College of Radiologists (iRefer).

This system is adept at guiding clinical referrers to select the most appropriate tests for patients, facilitating early diagnosis, tackling radiology waiting lists, and reducing clinician burnout. xWave Technologies, an Irish health technology company, is headquartered at NovaUCD in Dublin.

Mitchell O'Gorman, CEO of xWave Technologies, highlighted shared perspectives, noting Qure.ai's consistent appeal for collaboration since xWave's inception in 2020. Their collaborative goal centers on creating innovative diagnostic solutions to address critical global health challenges comprehensively.

Established in 2016 by Prashant Warier, founder & CEO, Qure.ai has solidified its presence as a globally recognised medical AI company. With headquarters in India and additional offices in London and New York, the company operates across more than 70 countries.

Qure.ai's certified medical imaging AI solutions cover a range of areas, including neurocritical trauma or stroke CTs, musculoskeletal X-ray fracture detection, and chest X-ray/CT for identifying lung cancer, TB, or heart failure. These solutions have been adopted by more than 25 UK NHS Trusts and Health Boards, as per the company website.

Previously, in July 2023, Qure.ai revealed a collaboration with a French company Therapixel. The partnership designates Qure.ai as the global distributor for Therapixel's MammoScreen, an AI-powered tool for enhancing early breast cancer detection. This joint effort aims to improve the precision and speed of breast cancer identification by empowering radiologists to interpret numerous screening mammograms in both 2D and 3D formats with heightened confidence.